Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.

"Declaration of personal interests : The authors thank all the investigators who contributed to this study. Statistical analysis was supported by Kyeong min Oh, Ah Rong Kim, Chung Hyun Choi, Hyun Wook, Park, Eun Ji Kim and Geun Seog Song who are employees of HK inno.N Corp., Seoul, Korea."

"Funding information"

"This phase 3 study was a multicentre study involving 33 investigators in 33 centres in South Korea. The study was a randomised, double‐blind, active‐controlled, comparative study designed to assess the non‐inferiority of tegoprazan 50 and 100 mg to lansoprazole 30 mg q.d. for 4 or 8 weeks in patients with GU. The protocol for this study was approved by the institutional review boards at each institute according to the Declaration of Helsinki and the International Congress on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use‐Good Clinical Practice guidelines. The study was registered with ClinicalTrials.gov under the number NCT02761512 (Study title: Study to Evaluate the Safety and Efficacy of CJ‐12420 in Patients with Gastric Ulcer)."